Natixis’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-391,993
| Closed | -$2.3M | – | 1178 |
|
|
2022
Q3 | $2.3M | Sell |
391,993
-8,539
| -2% | -$50.1K | 0.01% | 549 |
|
|
2022
Q2 | $1.74M | Buy |
400,532
+137,674
| +52% | +$598K | 0.01% | 659 |
|
|
2022
Q1 | $2.39M | Sell |
262,858
-798,838
| -75% | -$7.27M | 0.01% | 712 |
|
|
2021
Q4 | $21.7M | Buy |
1,061,696
+980,439
| +1,207% | +$20.1M | 0.07% | 218 |
|
|
2021
Q3 | $2.08M | Sell |
81,257
-5,940
| -7% | -$152K | 0.01% | 719 |
|
|
2021
Q2 | $3.05M | Buy |
87,197
+41,732
| +92% | +$1.46M | 0.01% | 459 |
|
|
2021
Q1 | $1.51M | Buy |
+45,465
| New | +$1.51M | 0.01% | 762 |
|
|
2020
Q2 | – | Sell |
-149,000
| Closed | -$456K | – | 829 |
|
|
2020
Q1 | $456K | Sell |
149,000
-90,831
| -38% | -$278K | ﹤0.01% | 589 |
|
|
2019
Q4 | $1.24M | Buy |
239,831
+114,131
| +91% | +$591K | 0.01% | 625 |
|
|
2019
Q3 | $649K | Sell |
125,700
-32,276
| -20% | -$167K | ﹤0.01% | 651 |
|
|
2019
Q2 | $956K | Buy |
+157,976
| New | +$956K | 0.01% | 539 |
|
|
2019
Q1 | – | Sell |
-49,736
| Closed | -$368K | – | 859 |
|
|
2018
Q4 | $368K | Buy |
+49,736
| New | +$368K | ﹤0.01% | 605 |
|
|
2017
Q4 | – | Sell |
-103,662
| Closed | -$544K | – | 1084 |
|
|
2017
Q3 | $544K | Buy |
+103,662
| New | +$544K | 0.01% | 658 |
|
|
2016
Q3 | – | Sell |
-30,000
| Closed | -$211K | – | 564 |
|
|
2016
Q2 | $211K | Buy |
+30,000
| New | +$211K | ﹤0.01% | 377 |
|
|
2014
Q1 | – | Sell |
-10,000
| Closed | -$52K | – | 577 |
|
|
2013
Q4 | $52K | Buy |
+10,000
| New | +$52K | ﹤0.01% | 537 |
|